Klaria Interim Report

Klaria interim report 1 January–31 March 2025

First quarter of 2024

The group in total

- Net sales 9.0 MSEK (0.1 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 3.4 MSEK (4.6 MSEK)

- Profit after tax amounted to -1.6 MSEK (-11.9 MSEK)

- Earnings per share for the quarter amounted to -0.01 SEK (-0.11 SEK)

- Cash flow from operating activities amounted to 0.9 MSEK (-7.8 MSEK)

- Liquid assets on the balance sheet date amounted to 1.5 MSEK (0.9 MSEK)

- Equity as of March 31 amounted to 1.7 MSEK 29.2 MSEK)

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.